The IGF-1/IGF-1 receptor (IGF-1R) pathway is now considered as a promising therapeutic target for TAO treatment, because OFs express IGF-1R, which potentiates TSHR signaling via formation of a functional complex with TSHR [22]. Here, IGF1 is linked to thromboangiitis obliterans.